U.S. markets closed

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.03-0.15 (-2.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close6.18
Open6.20
Bid4.80 x 800
Ask5.99 x 800
Day's Range5.75 - 6.21
52 Week Range3.30 - 13.35
Volume20,401
Avg. Volume17,021
Market Cap102.037M
Beta (5Y Monthly)0.07
PE Ratio (TTM)N/A
EPS (TTM)-2.27
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
    PR Newswire

    Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). Lucinactant is the Company's synthetic KL4 surfactant that is structurally similar to human pulmonary surfactant.

  • WINT: Clinical Studies Moving Forward For Both Lead Treatment Programs
    Zacks Small Cap Research

    WINT: Clinical Studies Moving Forward For Both Lead Treatment Programs

    By M. Marin NASDAQ:WINT READ THE FULL WINT RESEARCH REPORT Two Lead Drug Candidates; Multiple Programs Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharma and medical device company developing therapies for a range of acute cardiovascular and pulmonary conditions that necessitate critical care, including acute heart failure (AHF), cardiogenic shock (CS) due to heart failure, respiratory

  • Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates
    PR Newswire

    Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates

    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2020 and provided key business updates.